US 11,690,815 B2
Hyperkeratotic skin condition treatments and compositions
Jay Richard Ray, II, Conroe, TX (US)
Assigned to CMPD LICENSING LLC, Conroe, TX (US)
Filed by CMPD LICENSING, LLC, Conroe, TX (US)
Filed on May 3, 2018, as Appl. No. 15/970,340.
Application 15/970,340 is a continuation in part of application No. 14/990,168, filed on Jan. 7, 2016.
Application 14/990,168 is a continuation in part of application No. 15/597,936, filed on May 17, 2017, granted, now 10,105,342.
Application 15/597,936 is a continuation in part of application No. 15/668,184, filed on Aug. 3, 2017.
Application 15/597,936 is a continuation in part of application No. 15/440,800, filed on Feb. 23, 2017.
Application 15/440,800 is a continuation in part of application No. 14/975,172, filed on Dec. 18, 2015, granted, now 9,707,229, issued on Jul. 18, 2017.
Application 14/975,172 is a continuation in part of application No. 14/819,342, filed on Aug. 5, 2015.
Claims priority of provisional application 62/298,994, filed on Feb. 23, 2016.
Claims priority of provisional application 62/298,991, filed on Feb. 23, 2016.
Claims priority of provisional application 62/370,571, filed on Aug. 3, 2016.
Prior Publication US 2018/0250248 A1, Sep. 6, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/17 (2006.01); A61K 9/00 (2006.01); A61K 31/58 (2006.01); A61K 9/06 (2006.01); A61K 31/573 (2006.01)
CPC A61K 31/17 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01)] 4 Claims
 
1. A method of formulating a topical composition for treatment of a hyperkeratotic skin condition, the method comprising:
combining contents of a compounded capsule with a corticosteroid cream to formulate a topical composition for application to a skin area affected by hyperkeratosis,
wherein the contents of the capsule comprise urea bulk powder, and
wherein the step of combining the contents of the compounded capsule with the corticosteroid cream comprises stirring or folding the urea bulk powder into the corticosteroid cream,
wherein the corticosteroid cream comprises Clobetasol Propionate Cream, 0.05%, comprising cetyl alcohol, citric acid, glycol stearate, lanolin oil, methylparaben, PEG-8 stearate, polysorbate 60, propylene glycol, propylparaben, purified water, sodium citrate, stearyl alcohol, and white petrolatum, and
wherein the topical composition comprises between approximately 2.5% and approximately 50% urea by weight and between approximately 0.0250% and approximately 0.0488% clobetasol propionate by weight.